+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05951179

Phase 2 Open-Label Study Evaluating Safety and Efficacy of Intravesical TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

Led by Protara Therapeutics · Updated on 2026-08-24

131

Participants Needed

78

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.

CONDITIONS

Brief Title

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Research Team

C

Chief Scientific Operations Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here